CaviWipes1 are effective in killing 99.9% of bacteria, viruses and fungi in only 1 minute!

Product Options:

12 Canisters/Case (160 wipes/canister):
Part # ACP135100 Case $149.00



The Next Generation of Surface Disinfection!

CaviWipes1 Surface Disinfection Towelettes are a multi-purpose disinfectant/decontaminant wipe that can be used on hard, non-porous surfaces.  The improvements found in the latest formulation are effective in killing 99.9% of bacteria, viruses and fungi in 1 minute including TB, MDR A. baumannii, HIV-1, HCV and many more. When used as directed, the fragrance free CaviWipes1 Surface Disinfection Towelettes will effectively clean and disinfect surfaces and can help reduce the risk of cross contamination.

Features and Benefits of the CaviWipes1 Surface Disinfection Towelettes:

Features Benefits
1 Minute kill time Improved compliance & decreased risks of cross contamination
1 step cleaning & disinfecting* Improved staff efficiency & reduced costs
Clinically relevant efficacy claims Organisms that pose a threat in today’s environment
Conveniently packaged Ready-to-use; no dilution required
Materials compatibility Compatible with common hard, non-porous surfaces forund in the clinical environment.

* In the case of contamination with blood/other body fluids or when gross visible debris is present, a thorough cleaning of surfaces and objects must occur prior to disinfection.  In order for disinfection to occur properly, the disinfectant must be able to come in direct contact with the intended surface.


CaviWipes1 Surface Disinfection Towelettes Kill Claims:

Proven 1 minute Efficacy against 23 pathogens:

  • Mycobacterium tuberculosis va. bovis (BCG)
  • Staphylococcus aureus
  • Pseudomonas aeruginosa
  • Salmonella enterica
  • Trichophyton mentagrophytes
  • Candida albicans
  • Multi-Drug Resistant Acinetobacter baumannii
  • Klebsiella pneumoniae
  • Bordetella pertussis
  • ESBL Escherichia coli
  • Methicillin Resistant Staphylococcus aureus (MRSA)
  • Methicillin Resistant Staphylococcus epidermidis (MRSE)
  • Vancomycin Resistant Enterococcus faecalis (VRE)
  • Staphylococcus aureus with Reduced Susceptibility to Vancomycin
  • Vancomycin Intermediate Staphylococcus aureus (VISA)
  • Hepatitis B Virus (HBV)
  • Hepatitis C Virus (HCV)
  • Human Immunodeficiency Virus (HIV-1)
  • Herpes Simplex Virus Type 1
  • Herpes Simplex Virus Type 2
  • Human Coronavirus not associated with Severe Acute Respiratory Syndrome (SARS)
  • Influenza A, N3N2 Virus
  • Pandemic 2009 H1N1 Influenza A Virus